Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback